PTN News and Press, Palatin Technologies Inc. From 05/05/25

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy PR Newswire Topical melanocortin therapy shows promise for treating glaucoma PL9588 lowers intraocular pressure (IOP) by increasing a...

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease PR Newswire Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye disease....

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide PR Newswire Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression,...

Palatin Appeals NYSE American Notice of Delisting PR Newswire Company working aggressively to regain compliance Common stock to continue to trade on NYSE American during the appeal process CRANBURY, N.J. , April 14, 2025 /PRNewswire/ -- P...

2025-04-10 16:09:35 ET More on Palatin Technologies Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript Palatin reported promising results in trial for ulcerative colitis treatment Palatin's gets Orphan Drug status for its treatment for obesity from gen...

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal PR Newswire CRANBURY, N.J. , April 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company") (NYSE American:PTN), a biopharmaceutical company ...

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting PR Newswire Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Typ...

2025-03-31 17:30:05 ET More on Palatin Technologies Palatin reported promising results in trial for ulcerative colitis treatment Palatin's gets Orphan Drug status for its treatment for obesity from genetic disorder Seeking Alpha’s Quant Rating on Palatin Techn...

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study PR Newswire Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4%...

2025-03-28 09:19:02 ET More on Palatin Technologies Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript Palatin's gets Orphan Drug status for its treatment for obesity from genetic disorder Palatin Technologies prices 4.69M shares in direct offering ...